Exploring biomarkers in patients with advanced colorectal cancer receiving combined immunotherapy and anti-angiogenic treatment
Official title: A Biomarker Exploratory Study of Efficacy and Prognosis of Dual Blockade of PD1/PDL1 and CTLA4 in Combination of Anti-angiogenic Treatment in MSS Metastatic Colorectal Cancers and MSI Solid Tumors Refractory to PD1/PDL1 Antibody Monotherapy
Run by Peking University Cancer Hospital & Institute · NCT06549907 · Data updated 2026-11-12
This study is testing if combining two types of immunotherapy with an anti-cancer treatment can help people with advanced colorectal cancer who haven't responded to other therapies.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | Peking University Cancer Hospital & Institute Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Status | Recruiting |
| Started | January 10, 2024 |
| Main results expected | September 30, 2028 |
| Study ends | September 30, 2028 |
| Registry record updated | August 12, 2024 |
| Trial ID | NCT06549907 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include individuals with pathologically confirmed MSS metastatic colorectal cancers or MSI solid tumors that have not responded to PD-1/PD-L1 antibody monotherapy.
✕Probably not a fit
Patients with active malignancies outside the gastrointestinal system may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study focuses on patients with MSS metastatic colorectal cancer and MSI solid tumors that are resistant to PD-1/PD-L1 antibody monotherapy. It aims to identify clinical characteristics and biomarkers linked to the effects of dual PD1/PDL1 and CTLA4 blockade combined with anti-angiogenic therapy. The research will involve collecting various biological samples and utilizing multi-omics approaches, including single-cell sequencing and MRI imaging, to assess treatment responses over time. The study is conducted at Peking University Cancer Hospital, where patients will be monitored for clinical-pathological features and therapeutic outcomes.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies for patients with difficult-to-treat colorectal cancers.
How similar studies have gone: While similar approaches have been explored, this specific combination of therapies and multi-omics analysis is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Pathologically confirmed MSS metastatic colorectal cancers or MSI solid tumors refractory to PD1/PDL1 antibody monotherapy * Receiving dual blockade of PD1/PDL1 and CTLA4 in combination of anti-angiogenic treatment with or without other therapies Exclusion Criteria: ●Having malignancies in non-gastrointestinal system that have not been cured (Lynch syndrome not included)
Where it's running
-
Jian Li
Beijing, Beijing Municipality, China Recruiting
Study contacts
- Study coordinator: Zhenghang Wang
- Email: zhenghang_wang@bjmu.edu.cn
- Phone: 18813186790
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Adding pelareorep to FOLFIRI and bevacizumab for second-line RAS‑mutated, MSS metastatic colorectal cancer
This trial tests whether adding the oncolytic virus pelareorep to standard FOLFIRI plus bevacizumab helps people with RAS‑mutated, microsatellite‑stable metastatic colorectal cancer who progressed after first‑line oxaliplatin therapy.
-
Combining Fruquintinib, Adebrelimab, and Radiotherapy for Advanced Colorectal Cancer
This study is testing a new treatment that combines Fruquintinib, Adebrelimab, and radiotherapy to see if it can help people with advanced colorectal cancer who haven't responded to other treatments.
-
Treatment for advanced colorectal cancer using a new drug combination
This study is testing a new combination of oral and intravenous medications to see if it can help people with advanced colorectal cancer that hasn't responded to previous treatments.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.